Core Insights - The FDA has granted multiple approvals for new treatments across various therapeutic areas, including oncology and rare genetic disorders, in late February and early March 2026 Group 1: Boehringer Ingelheim Pharmaceuticals Inc. - The FDA granted accelerated approval to Hernexeos as a first-line treatment for adult patients with advanced non-small cell lung cancer (NSCLC) with HER2 mutations on February 26, 2026 [2] - Hernexeos is the first targeted therapy for HER2-mutant advanced NSCLC in the first-line setting, with HER2 mutations occurring in approximately 2-4% of NSCLC cases [3] Group 2: Ascendis Pharma A/S - Ascendis received accelerated approval for Yuviwel, a once-weekly treatment for children aged 2 years and older with achondroplasia on February 27, 2026 [4] - Yuviwel is the first and only approved therapy providing continuous systemic exposure to C-type natriuretic peptide (CNP) over a weekly dosing interval [6] Group 3: BioMarin Pharmaceutical Inc. - BioMarin expanded the indication of Palynziq to include pediatric patients aged 12 years and older with phenylketonuria (PKU) on February 27, 2026 [7] - Palynziq is the only enzyme substitution therapy approved to reduce blood phenylalanine concentrations in PKU patients, generating $433 million in revenue in 2025, up from $355 million in 2024 [9] Group 4: Novo Nordisk A/S - Novo Nordisk received FDA approval for three new indications for Sogroya, a long-acting growth hormone, on February 27, 2026 [10] - Sogroya is now approved for children aged 2.5 years and older with Idiopathic Short Stature, short stature born Small for Gestational Age, and growth failure associated with Noonan Syndrome [11] - The once-weekly administration of Sogroya aims to improve adherence compared to daily growth hormone injections [12] Group 5: Johnson & Johnson - The FDA approved Tecvayli plus Darzalex Faspro for adults with relapsed or refractory multiple myeloma on March 5, 2026 [13] - Tecvayli received accelerated approval in October 2022 as a subcutaneous treatment for patients with RRMM who have undergone multiple prior therapies [14] - Darzalex Faspro is already approved for multiple indications in multiple myeloma, enhancing treatment options for patients [15]